web analytics
10.3 C
Munich
Sunday, September 25, 2022

The Inside Scoop of Arch Therapeutics Inc (OTCBB:ARTH)

Arch Therapeutics Inc (OTCBB:ARTH) is making a strong move up after the Company announced a $3,066,000 in equity financing in a private placement to 19 accredited investors.

According to the pr ARTH raised $3,066,000 in equity financing in a private placement to 19 accredited investors (the “Investors”) on June 30, 2015 and anticipates raising up to an additional $100,000 before concluding the private placement. At the Initial Closing, the Company sold and the Investors purchased 13,936,367 Units at a purchase price of $0.22 per Unit. Each Unit consisted of a share of the Company’s common stock, par value $0.001 per share (“Common Stock”), and a Series D Warrant to purchase a share of Common Stock at an exercise price of $0.25 per share at any time prior to the fifth anniversary of the issuance date of the Series D Warrant. Upon raising the final $100,000 in expected financing, a total of 14,390,913 Units will have been issued in connection with the 2015 Private Placement Financing, and the number of outstanding shares of Common Stock will increase from 78,081,487 to 92,472,400.

ARTH was the subject of a significant promotion last summer shortly after hitting the bb’s from The Bedford Report, The Paragon Report and Five Star Equities also responsible for the fairly successful recent promotion of ECAU which managed gains of well over 500%.

Arch Therapeutics Inc (OTCBB:ARTH) is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch’s flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device (TM), is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

In April the Company announced an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded fibrin sealant that is indicated for use in controlling bleeding.

In this study, full thickness penetrating wounds were surgically created in rat livers, which are highly vascularized parenchymal organs, and then either AC5(TM) or the fibrin sealant was applied in order to stop the bleeding. The time to hemostasis (TTH), which is the time required to stop bleeding, was measured.

The average TTH after application of AC5 was significantly less than 30 seconds. The average TTH for the fibrin sealant was approximately 50% longer.

AC5 was maintained at room temperature without requiring cold storage, whereas the fibrin sealant was maintained frozen during storage, in accordance with its prescribing directions. This is a common constraint of many commercial hemostatic agents that are derived from blood-products. Such products also require a multi-step preparation procedure prior to use.

AC5 contains a self-assembling peptide comprising naturally occurring amino acids that are not sourced from humans or animals, whereas the fibrin sealant is made from pooled human plasma (blood product). Fibrin sealants and other products that are sourced from human or animal blood products can contain infectious agents, such as viruses and potentially the Creutzfeldt-Jakob disease (CJD) agent, which potentially can be transferred to a patient.

To Find out the inside Scoop on ARTH Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The study group intends to submit the data for publication, at which time additional details would be made publicly available. This animal trial was conducted as part of an ongoing series of studies comparing AC5 with currently marketed hemostatic products that are used in surgical procedures.

CEO Terrence W. Norchi, MD said “AC5 has again shown promising results. Data from the preclinical studies conducted to date indicates that AC5 has favorable efficacy when compared to a number of other popular hemostatic agents. Furthermore, data to date continues to support that it is both easy to use and non-toxic. Compared to the products on the market that are sourced from humans or animals, AC5 is instead manufactured synthetically from amino acids that are not derived from humans or other animals, and therefore, would not be expected to carry that particular risk factor.”

The research was led by Rudolf Urbanics, MD, PhD, and Domokos Csukas, DVM at Semmelweis University Faculty of Medicine in Budapest, Hungary within the Department of Surgical Research and Techniques. The research was sponsored by Arch. Also part of the research team was Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine Translational Think Tank in the Department of Ophthalmology at the Medical Faculty Mannheim of the University of Heidelberg in Germany. Dr. Ellis-Behnke is also affiliated with three U.S. academic institutions, and he is an advisor to and co-founder of Arch.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $17 million market valuation ARTH does have $782,000 in the treasury, no revenues to date, a high burn rate and rising short term debt. But one has to be excited by the favorable preclinical data from an independent study of AC5 Surgical Hemostatic Device(TM) versus a popular Fibrin Sealant. We will be updating on ARTH when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ARTH.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ARTH either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.